{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:02:56Z","timestamp":1780480976714,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05458"],"award-info":[{"award-number":["19H05458"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["MOE-113-YSFMN-0005-002-P1"],"award-info":[{"award-number":["MOE-113-YSFMN-0005-002-P1"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007750","name":"National Cheng Kung University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jconrel.2025.114256","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:13:16Z","timestamp":1758575596000},"page":"114256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enzyme-responsive oleoylethanolamide-releasing nanomedicine for sustained liver delivery and therapeutic improvement in early-stage metabolic dysfunction-associated steatohepatitis (MASH)"],"prefix":"10.1016","volume":"387","author":[{"given":"Yuanyuan","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Shashni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114256_bb0005","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.114256_bb0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.jconrel.2025.114256_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0025","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.114256_bb0030","first-page":"40","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail","volume":"9","author":"Sharma","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-1877-9656","article-title":"Nonalcoholic steatohepatitis drug development pipeline: an update","volume":"42","author":"Chew","year":"2022","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2025.114256_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms17091575","article-title":"Molecular pathogenesis of NASH","volume":"17","author":"Caligiuri","year":"2016","journal-title":"IJMS"},{"key":"10.1016\/j.jconrel.2025.114256_bb0045","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biology11050792","article-title":"PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)","volume":"11","author":"Todisco","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.jconrel.2025.114256_bb0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0055","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.2174\/1381612811319170020","article-title":"The role of fibrate treatment in dyslipidemia: an overview","volume":"19","author":"Katsiki","year":"2013","journal-title":"CPD"},{"key":"10.1016\/j.jconrel.2025.114256_bb0060","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nri912","article-title":"Emerging roles of PPARS in inflammation and immunity","volume":"2","author":"Daynes","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0065","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1021\/jm5004733","article-title":"Small molecule inhibitors targeting activator protein 1 (AP-1): miniperspective","volume":"57","author":"Ye","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.114256_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cvr\/cvq076","article-title":"The nuclear factor-B-interleukin-6 signalling pathway mediating vascular inflammation","volume":"86","author":"Brasier","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2025.114256_bb0075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.intimp.2010.07.007","article-title":"PPAR\u03b1 contributes to colonic protection in mice with DSS-induced colitis","volume":"10","author":"Azuma","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0080","doi-asserted-by":"crossref","first-page":"e1397","DOI":"10.1038\/cddis.2014.361","article-title":"Peroxisome proliferator-activated receptor \u03b1 activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway","volume":"5","author":"Jiao","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.114256_bb0085","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1038\/s41598-020-63579-3","article-title":"Hepatocyte-specific deletion of Ppar\u03b1 promotes NAFLD in the context of obesity","volume":"10","author":"R\u00e9gnier","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2025.114256_bb0090","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.114256_bb0095","doi-asserted-by":"crossref","first-page":"42530","DOI":"10.18632\/oncotarget.6466","article-title":"Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2025.114256_bb0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2025.114256_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114256_bb0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/obr.12853","article-title":"The effects of oleoylethanolamide, an endogenous PPAR-\u03b1 agonist, on risk factors for NAFLD: a systematic review","volume":"20","author":"Tutunchi","year":"2019","journal-title":"Obes. Rev."},{"key":"10.1016\/j.jconrel.2025.114256_bb0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jphs.2014.12.001","article-title":"Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats","volume":"127","author":"Li","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.114256_bb0120","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/antiox10081289","article-title":"Oleoylethanolamide reduces hepatic oxidative stress and endoplasmic reticulum stress in high-fat diet-fed rats","volume":"10","author":"Giudetti","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.jconrel.2025.114256_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/jpet.106.105221","article-title":"Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties","volume":"318","author":"Astarita","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2025.114256_bb0130","article-title":"Oleoylethanolamide-induced anorexia in rats is associated with locomotor impairment","volume":"6","author":"Fedele","year":"2018","journal-title":"Phys. Rep."},{"key":"10.1016\/j.jconrel.2025.114256_bb0135","first-page":"R729","article-title":"Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity","volume":"289","author":"Proulx","year":"2005","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.jconrel.2025.114256_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/35102582","article-title":"An anorexic lipid mediator regulated by feeding","volume":"414","author":"Rodr\u00edguez De Fonseca","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.114256_bb0145","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.2147\/IJN.S344318","article-title":"Endogenous oleoylethanolamide crystals loaded lipid nanoparticles with enhanced hydrophobic drug loading capacity for efficient stroke therapy","volume":"16","author":"Wu","year":"2021","journal-title":"IJN"},{"key":"10.1016\/j.jconrel.2025.114256_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.msec.2019.01.071","article-title":"Improved anti-obesity effect of herbal active and endogenous lipids co-loaded lipid nanocarriers: preparation, in vitro and in vivo evaluation","volume":"99","author":"Lacatusu","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2025.114256_bb0155","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1021\/acs.langmuir.6b02395","article-title":"Incorporation of an endogenous neuromodulatory lipid, oleoylethanolamide, into cubosomes: nanostructural characterization","volume":"32","author":"Younus","year":"2016","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2025.114256_bb0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharma. Sci."},{"key":"10.1016\/j.jconrel.2025.114256_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal route of drug administration: should it be used in experimental animal studies?","volume":"37","author":"Al Shoyaib","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2025.114256_bb0170","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jconrel.2024.10.032","article-title":"Size-dependent translocation and lymphatic transportation of polymeric nanocarriers post intraperitoneal administration","volume":"376","author":"Cai","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.114256_bb0175","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1021\/acs.molpharmaceut.9b00855","article-title":"Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties","volume":"16","author":"Lee","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114256_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115304","article-title":"Interactions between nanoparticles and lymphatic systems: mechanisms and applications in drug delivery","volume":"209","author":"Tang","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.114256_bb0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2016","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.114256_bb0190","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1021\/acs.molpharmaceut.0c00559","article-title":"Characterization of differential tissue abundance of major non-CYP enzymes in human","volume":"17","author":"Basit","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.114256_bb0195","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.3390\/ijms22115851","article-title":"One week of CDAHFD induces steatohepatitis and mitochondrial dysfunction with oxidative stress in liver","volume":"22","author":"Sugasawa","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.jconrel.2025.114256_bb0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1049\/nbt2.12018","article-title":"Nanomicelles: types, properties and applications in drug delivery","volume":"15","author":"Bose","year":"2021","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0205","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res"},{"key":"10.1016\/j.jconrel.2025.114256_bb0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","article-title":"Polymeric micelle stability","volume":"7","author":"Owen","year":"2012","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2025.114256_bb0215","article-title":"Pig liver esterases hydrolyze endocannabinoids and promote inflammatory response","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120877","article-title":"Design of enzyme-responsive short-chain fatty acid-based self-assembling drug for alleviation of type 2 diabetes mellitus","volume":"275","author":"Shashni","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.114256_bb0225","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/jssc.202001210","article-title":"A sensitive LC-MS\/MS method for the study of exogenously administered 13C-oleoylethanolamide in rat plasma and brain tissue","volume":"44","author":"Prentice","year":"2021","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jconrel.2025.114256_bb0230","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/15376516.2014.898356","article-title":"Troubleshooting in LC-MS\/MS method for determining endocannabinoid and endocannabinoid-like molecules in rat brain structures applied to assessing the brain endocannabinoid\/endovanilloid system significance","volume":"24","author":"Bystrowska","year":"2014","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.jconrel.2025.114256_bb0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cbi.2011.12.006","volume":"195","author":"Duysen","year":"2012","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jconrel.2025.114256_bb0240","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: Ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0245","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/biom11020241","article-title":"\u201cCell membrane theory of senescence\u201d and the role of bioactive lipids in aging, and aging associated diseases and their therapeutic implications","volume":"11","author":"Das","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2025.114256_bb0250","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00109-008-0305-7","article-title":"Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice","volume":"86","author":"Aviello","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jconrel.2025.114256_bb0255","first-page":"129","article-title":"Oleoylethanolamide enhances \u03b2-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat","volume":"7","author":"Su\u00e1rez","year":"2014","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.jconrel.2025.114256_bb0260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pain.2007.03.008","article-title":"Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain","volume":"133","author":"Suard\u00edaz","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.jconrel.2025.114256_bb0265","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1440-1681.13238","article-title":"A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-\u03b1, on the management and prevention of obesity","volume":"47","author":"Tutunchi","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.34172\/hpp.2020.56","article-title":"Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: a clinical trial","volume":"10","author":"Tutunchi","year":"2020","journal-title":"Health Promot. Perspect."},{"key":"10.1016\/j.jconrel.2025.114256_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164191","article-title":"Evaluation of methionine content in a high-fat and choline-deficient diet on body weight gain and the development of non-alcoholic steatohepatitis in mice","volume":"11","author":"Chiba","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.114256_bb0280","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1002\/2211-5463.13272","article-title":"Nonobese mice with nonalcoholic steatohepatitis fed on a choline-deficient, l-amino acid-defined, high-fat diet exhibit alterations in signaling pathways","volume":"11","author":"Suzuki-Kemuriyama","year":"2021","journal-title":"FEBS Open Bio."},{"key":"10.1016\/j.jconrel.2025.114256_bb0285","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/nu10050653","article-title":"Choline supplementation prevents a hallmark disturbance of kwashiorkor in weanling mice fed a maize vegetable diet: hepatic steatosis of undernutrition","volume":"10","author":"May","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jconrel.2025.114256_bb0290","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.jconrel.2025.114256_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153798","article-title":"Stage-dependent expression of fibrogenic markers in alcohol-related liver disease","volume":"231","author":"S\u00f8rensen","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.jconrel.2025.114256_bb0300","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/apt.15219","article-title":"Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease","volume":"49","author":"Buzzetti","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2025.114256_bb0305","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1023\/B:PHAM.0000041444.06122.8d","article-title":"Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future","volume":"21","author":"Van Raalte","year":"2004","journal-title":"Pharm. Res."}],"updated-by":[{"DOI":"10.1016\/j.jconrel.2025.114352","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000}}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925008685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925008685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:07:09Z","timestamp":1780477629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925008685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":61,"alternative-id":["S0168365925008685"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114256","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme-responsive oleoylethanolamide-releasing nanomedicine for sustained liver delivery and therapeutic improvement in early-stage metabolic dysfunction-associated steatohepatitis (MASH)","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114256"}}